癌症研究
细胞毒性
免疫系统
克拉斯
激酶
免疫疗法
蛋白激酶A
自然杀伤细胞
肺癌
细胞
生物
癌细胞
癌症
免疫学
药理学
医学
细胞生物学
肿瘤科
体外
生物化学
结直肠癌
遗传学
作者
Marcus Ruscetti,Josef Leibold,Matthew J. Bott,Myles Fennell,Amanda Kulick,Nelson R. Salgado,Chi-Chao Chen,Yu-Jui Ho,Francisco J. Sánchez‐Rivera,Judith Feucht,Timour Baslan,Sha Tian,Hsuan-An Chen,Paul B. Romesser,John T. Poirier,Charles M. Rudin,Elisa de Stanchina,Eusebio Manchado,Charles J. Sherr,Scott W. Lowe
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2018-12-20
卷期号:362 (6421): 1416-1422
被引量:433
标识
DOI:10.1126/science.aas9090
摘要
Molecularly targeted therapies aim to obstruct cell autonomous programs required for tumor growth. We show that mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 4/6 inhibitors act in combination to suppress the proliferation of KRAS-mutant lung cancer cells while simultaneously provoking a natural killer (NK) cell surveillance program leading to tumor cell death. The drug combination, but neither agent alone, promotes retinoblastoma (RB) protein-mediated cellular senescence and activation of the immunomodulatory senescence-associated secretory phenotype (SASP). SASP components tumor necrosis factor-α and intercellular adhesion molecule-1 are required for NK cell surveillance of drug-treated tumor cells, which contributes to tumor regressions and prolonged survival in a KRAS-mutant lung cancer mouse model. Therefore, molecularly targeted agents capable of inducing senescence can produce tumor control through non-cell autonomous mechanisms involving NK cell surveillance.
科研通智能强力驱动
Strongly Powered by AbleSci AI